US clinical-stage biotech AzurRx BioPharma (Nasdaq: AZRX) saw its shares rocket almost 32% to $0.69 yesterday, after it reported some positive mid-stage trials results for its cystic fibrosis candidate MS1819.
AzurRx announced positive top-line results from its Phase II combination trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).
Just a day earlier, AzurRx announced that the World Health Organization (WHO) has published “adrulipase alfa” as the proposed International Nonproprietary Name (INN) for MS1819.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze